Impact of High-Flow Nasal Cannula Use in Subjects With COVID-19 ARDS at High Altitudes: Clinical Presentation and Prognostic Factors

Simple item page
dc.contributor.authorDaniel Molano-Franco
dc.contributor.authorAntonio Viruez‐Soto
dc.contributor.authorMario Gómez
dc.contributor.authorEdgar Beltrán
dc.contributor.authorMario Villabon
dc.contributor.authorÁngela Sosa
dc.contributor.authorLeidy Ortiz
dc.contributor.authorEstefania Orozco
dc.contributor.authorAlejandra Hurtado
dc.contributor.authorLida Sanchez
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T15:35:34Z
dc.date.available2026-03-22T15:35:34Z
dc.date.issued2023
dc.descriptionCitaciones: 1
dc.description.abstractHigh-altitude subjects treated with HFNC for COVID-19 showed a high risk of respiratory failure and progressive hypoxemia when F<sub>IO<sub>2</sub></sub> requirements were > 0.8 after 24 h of treatment. In these subjects, personalized management should include continuous monitoring of individual clinical conditions (such as oxygenation indices, with cutoffs adapted to those corresponding to high-altitude cities).
dc.identifier.doi10.4187/respcare.10839
dc.identifier.urihttps://doi.org/10.4187/respcare.10839
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/53267
dc.language.isoen
dc.publisherAmerican Association for Respiratory Care
dc.relation.ispartofRespiratory Care
dc.sourceFundación Universitaria de Ciencias de la Salud
dc.subjectNasal cannula
dc.subjectMedicine
dc.subjectOdds ratio
dc.subjectHypoxemia
dc.subjectOxygen therapy
dc.subjectARDS
dc.subjectProspective cohort study
dc.subjectAnesthesia
dc.subjectInternal medicine
dc.titleImpact of High-Flow Nasal Cannula Use in Subjects With COVID-19 ARDS at High Altitudes: Clinical Presentation and Prognostic Factors
dc.typearticle

Files

Collections

Artículo Científico Publicado